ArticleEJNMMI radiopharmacy and chemistry2023
Site-specific
Article in EJNMMI radiopharmacy and chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Chelator Conjugation Chemistry Matters: Squaramide Linker Enhances Tumor Contrast inACS omega · 2026Article
- CRISPR-Cas9-mediated therapeutics: Current clinical trials and therapy approval landscape to treat human diseases.Molecular therapy. Nucleic acids · 2026Review
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- CD70: An emerging target for integrated cancer diagnosis and therapy.Clinical and translational medicine · 2025Review
- Unveiling the potential of copper-61 vs. gallium-68 for SSTR PET imaging.European journal of nuclear medicine and molecular imaging · 2025Article
- Development and Preclinical Evaluation of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- PET imaging of HIV-1 envelope protein gp120 usingiScience · 2025Article
- Transforming cancer treatment: integrating patient-derived organoids and CRISPR screening for precision medicine.Frontiers in pharmacology · 2025Review
- Development and evaluation of a single domain antibody targeting folate receptor alpha for radioligand therapy.Journal of nanobiotechnology · 2024Article
- Site-specific bioconjugation and nuclear imaging.Current opinion in chemical biology · 2024Review
- Engineered Antibodies as Cancer Radiotheranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- CRISPR technology in human diseases.MedComm · 2024Review
- ImmunoPET/CT imaging of clear cell renal cell carcinoma with [European journal of nuclear medicine and molecular imaging · 2024Article
- Advancements in nuclear imaging using radiolabeled nanobody tracers to support cancer immunotherapy.Immunotherapy advances · 2024Review
- Small Antibodies with Big Applications: Nanobody-Based Cancer Diagnostics and Therapeutics.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundCD70-CD27 is a costimulatory ligand-receptor pair in the tumor necrosis factor receptor family. With only limited expression in normal tissues, CD70 is constitutively expressed in a variety of solid tumors and hematologic malignancies, facilitating immunosuppression through CD27 signaling in the tumor microenvironment by enhanced survival of regulatory T cells, induction of T cell apoptosis, and T cell exhaustion. Consequently, CD70 is an increasingly recognized target for developing antibody-based therapies, but its expression patterns vary among different tumor types in spatial distribution, magnitude of expression and percentage of positive cells. In that regard, individual confirmation of CD70 expression at screening and during treatment could enhance the successful implementation of anti-CD70 therapies. Here, we developed a gallium-68 (
resultsAn anti-CD70 VHH construct containing a C-direct-tag with a free thiol was developed to enable site-specific conjugation to a NOTA bifunctional chelator for
conclusion[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.